Nasdaq · CIK 0001691082
LBRX LB PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing Sep 29, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Signals
Open-market buys and sells at LB PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Vida Ventures GP III, L.L.C. owner buy | $5.0M 333,333 shares | +61% | - | |
| 57Moderate | Deep Track Biotechnology Master Fund, Ltd. owner buy | $40M 2,666,666 shares | +389% | - | |
| 65Notable | Ran Nussbaum director buy | $15M 1,000,000 shares | +243% | - | |
| 57Moderate | Pontifax Management 4 G.P. (2015) Ltd. owner buy | $15M 1,000,000 shares | +243% | - |
Transactions
The last 70 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -3,944 | - | - | 0 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,944 | - | - | 3,944 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -896 | - | - | 0 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +896 | - | - | 896 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -1,255 | - | - | 0 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,255 | - | - | 1,255 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -14,343 | - | - | 0 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,343 | - | - | 14,343 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -7,171 | - | - | 0 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +7,171 | - | - | 7,171 | Sep 29, 2025 |
| Sep 10, 2025 | Marc L Panoff Senior Vice President, Finance | AGrant or award Employee Stock Option (Right to Buy)derivative | +90,525 | $0.00 | $0 | 90,525 | Sep 29, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | CConversion Common Stockindirect: By Vida Ventures III, L.P. | +547,648 | - | - | 547,648 | Sep 16, 2025 |
| Sep 12, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | CConversion Common Stock | +686,138 | - | - | 686,138 | Sep 16, 2025 |
| Sep 12, 2025 | Ran Nussbaum director | CConversion Common Stockindirect: See footnote | +411,681 | - | - | 411,681 | Sep 16, 2025 |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. owner | CConversion Common Stockindirect: See footnote | +411,681 | - | - | 411,681 | Sep 16, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | CConversion Common Stockindirect: By Vida Ventures III-A, L.P. | +1,262 | - | - | 1,262 | Sep 16, 2025 |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. owner | POpen-market purchase Common Stockindirect: See footnote | +1,000,000 | $15.00 | $15M | 1,411,681 | Sep 16, 2025 |
| Sep 12, 2025 | Ran Nussbaum director | POpen-market purchase Common Stockindirect: See footnote | +1,000,000 | $15.00 | $15M | 1,411,681 | Sep 16, 2025 |
| Sep 12, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | POpen-market purchase Common Stock | +2,000,000 | $15.00 | $30M | 2,686,138 | Sep 16, 2025 |
| Sep 12, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | POpen-market purchase Common Stockindirect: By Deep Track Special Opportunities Fund, LP | +666,666 | $15.00 | $10.0M | 666,666 | Sep 16, 2025 |
| Sep 12, 2025 | Pontifax Management 4 G.P. (2015) Ltd. owner | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -10,000,000 | - | - | 0 | Sep 16, 2025 |
| Sep 12, 2025 | Ran Nussbaum director | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -10,000,000 | - | - | 0 | Sep 16, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | POpen-market purchase Common Stockindirect: By Vida Ventures III, L.P. | +332,566 | $15.00 | $5.0M | 880,214 | Sep 16, 2025 |
| Sep 12, 2025 | Deep Track Biotechnology Master Fund, Ltd. owner | CConversion Series C Preferred Stockderivative | -16,666,667 | - | - | 0 | Sep 16, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | POpen-market purchase Common Stockindirect: By Vida Ventures III-A, L.P. | +767 | $15.00 | $12k | 2,029 | Sep 16, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | CConversion Series C Preferred Stockderivativeindirect: By Vida Ventures III, L.P. | -13,302,666 | $0.00 | $0 | 0 | Sep 16, 2025 |
| Sep 12, 2025 | Vida Ventures GP III, L.L.C. owner | CConversion Series C Preferred Stockderivativeindirect: By Vida Ventures III-A, L.P. | -30,667 | $0.00 | $0 | 0 | Sep 16, 2025 |
| Sep 10, 2025 | Ran Nussbaum director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | Heather D Turner Chief Executive Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -175,706 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,792 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Richard Anthony Silva SVP, Technical Operations | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -8,964 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Rebecca Luse director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,944 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Gad Soffer Chief Business Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -26,893 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | William P Kane Jr director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | Rekha Hemrajani director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | J. Scott Garland director | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -17,929 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Anna Eramo Chief Medical Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -26,893 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Anna Eramo Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +26,893 | - | - | 26,893 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +1,792 | - | - | 1,792 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +3,944 | - | - | 3,944 | Sep 12, 2025 |
| Sep 10, 2025 | J. Scott Garland director | AGrant or award Employee Stock Option (Right to Buy)derivative | +17,929 | - | - | 17,929 | Sep 12, 2025 |
| Sep 10, 2025 | Heather D Turner Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +175,706 | - | - | 175,706 | Sep 12, 2025 |
| Sep 10, 2025 | Gad Soffer Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +26,893 | - | - | 26,893 | Sep 12, 2025 |
| Sep 10, 2025 | Richard Anthony Silva SVP, Technical Operations | AGrant or award Employee Stock Option (Right to Buy)derivative | +8,964 | - | - | 8,964 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | DDisposition to issuer Stock Option (Right to Buy)derivative | -896 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Anna Eramo Chief Medical Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -6,275 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | J. Scott Garland director | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -3,585 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Heather D Turner Chief Executive Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -7,857 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | DDisposition to issuer Stock Option (Right to Buy)derivative | -717 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Gad Soffer Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +229,860 | $0.00 | $0 | 229,860 | Sep 12, 2025 |
| Sep 10, 2025 | Richard Anthony Silva SVP, Technical Operations | AGrant or award Employee Stock Option (Right to Buy)derivative | +80,899 | $0.00 | $0 | 80,899 | Sep 12, 2025 |
| Sep 10, 2025 | Heather D Turner Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +7,857 | - | - | 7,857 | Sep 12, 2025 |
| Sep 10, 2025 | Anna Eramo Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +6,275 | - | - | 6,275 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +896 | - | - | 896 | Sep 12, 2025 |
| Sep 10, 2025 | J. Scott Garland director | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,585 | - | - | 3,585 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +717 | - | - | 717 | Sep 12, 2025 |
| Sep 10, 2025 | Heather D Turner Chief Executive Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +971,828 | $0.00 | $0 | 971,828 | Sep 12, 2025 |
| Sep 10, 2025 | J. Scott Garland director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,757 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,255 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Anna Eramo Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +155,812 | $0.00 | $0 | 155,812 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +10,757 | - | - | 10,757 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +1,255 | - | - | 1,255 | Sep 12, 2025 |
| Sep 10, 2025 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,929 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +17,929 | - | - | 17,929 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | DDisposition to issuer Stock Option (Right to Buy)derivative | -53,787 | - | - | 0 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +53,787 | - | - | 53,787 | Sep 12, 2025 |
| Sep 10, 2025 | Zachary Prensky director | AGrant or award Stock Option (Right to Buy)derivative | +22,449 | $0.00 | $0 | 22,449 | Sep 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Deep Track Biotechnology Master Fund, Ltd.owner
- Anna EramoChief Medical Officer
- J. Scott Garlanddirector
- Rekha Hemrajanidirector
- William P Kane Jrdirector
- Rebecca Lusedirector
- Ran Nussbaumdirector, owner
- Marc L PanoffSenior Vice President, Finance
- Zachary Prenskydirector
- Pontifax Management 4 G.P. (2015) Ltd.owner
- Robert R Ruffolodirector
- Richard Anthony SilvaSVP, Technical Operations
- Gad SofferChief Business Officer
- Heather D TurnerChief Executive Officer
- Vida Ventures GP III, L.L.C.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.